Tesamorelin

Growth hormone Approved · US Human trials

Also called Egrifta

The full 44-amino-acid growth-hormone-releasing hormone with a small fatty group added at one end to slow its breakdown. It raises the body's own growth hormone and IGF-1 and reduces deep abdominal fat. It is also studied for fatty liver and mild cognitive impairment.

Why people take it

Visceral belly fatLiver fatLean muscle preservationGrowth hormone support

What studies report

Roughly 15-18% reduction in visceral abdominal fat in HIV lipodystrophy trials
Reduced liver fat in people with HIV and fatty liver
Modest cognitive signals in mild cognitive impairment studies

How it works

A GHRH analogue that stimulates natural pulsatile growth hormone release; its signature effect is on visceral fat.

In practice Off-label

Used specifically for visceral fat rather than general weight loss
Run for longer periods than most peptides, since the fat returns when stopped

Reported real-world use, not evidence and not a recommendation.

Worth knowing: Visceral fat returns when it is stopped. It can worsen glucose tolerance.

Status: FDA-approved (Egrifta, 2010) for excess abdominal fat in people with HIV-associated lipodystrophy.

Route: Subcutaneous injection, prescribed where approved
Formula: C221H366N72O67S
Molecular weight: 5135.9 g/mol
CAS: 218949-48-5
Available as: 10 mg

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.